Serving hundreds of leading biopharmaceutical companies globally:

Generated: December 12, 2018

DrugPatentWatch Database Preview

AVASTIN Drug Profile

« Back to Dashboard

Summary for Tradename: AVASTIN

Patents:	657
Applicants:	1
BLAs:	1
Suppliers: see list	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AVASTIN

Pharmacology for AVASTIN

Mechanism of Action	Vascular Endothelial Growth Factor Receptor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions

US Patents for AVASTIN

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	002	2004-02-26	➤ Sign Up	Bayer Intellectual Property GMBH (Monheim, DE)	➤ Sign Up	RX		search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	002	2004-02-26	➤ Sign Up	THE PENN STATE RESEARCH FOUNDATION (University Park, PA)	➤ Sign Up	RX		search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	002	2004-02-26	➤ Sign Up	Moerae Matrix, Inc. (Morristown, NJ)	➤ Sign Up	RX		search
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source

International Patents for AVASTIN

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Spain	2315664	➤ Sign Up
Japan	5437563	➤ Sign Up
World Intellectual Property Organization (WIPO)	2004043377	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for AVASTIN

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0238	Netherlands	➤ Sign Up	PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060630
0753	Netherlands	➤ Sign Up	PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
23/2006	Austria	➤ Sign Up	PRODUCT NAME: NATALIZUMAB
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow

US Department of Justice

Mallinckrodt

Harvard Business School

Deloitte

Cipla

Covington

Teva

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.